Orgenesis announced that it is partnering with CGT Global. The two companies are collaborating to leverage CGT Global's extensive network of CGT Clinics and Healthcare partnerships to expand commercialization of CGTs in California and other US locations. Resources will be aligned to place technology-agnostic Octomera Mobile Processing Units & Labs (OMPULs) for leukapheresis and the production of CAR-T and TILS products.

The Company expects the footprint to grow as CGT Global partners with 32 hospitals and anticipates partnering with over 200 hospitals by the end of 2024. Since 2010, the CGT Global team has been dedicated to accelerating patient care and access by facilitating all components of the industry from R&D to clinical trials, drug manufacturing, and hospital partnerships. Their focus has remained acutely on the urgency of these products and therapies so that the landscape of medical care will be improved.

CGT Global has created a bicoastal network of CGT Clinics in the US using technology and specialized training in leukapheresis. CGT Global will provide expertise gained from being a leading provider of cellular manufacturing, biomedical therapeutic collections, and services through their existing network of CGT clinics and hospital footprint. Octomera will provide services and support, as well as placement of agnostic OMPULs that are designed to standardize CGT production processes for quality and regulatory compliance across the globe at a fraction of the cost.

The OMPULs will be designed based on the process, with consideration for regulatory compliance and quality management with centralized data and IT solutions. The OMPULs can be installed in six months within an existing structure or available outdoor space, and production capacity can easily be scaled through additional units.